drug safety – mycolab.ai

Psychedelics: Safety and Efficacy

mycolabadmin

This paper reviews scientific research on psychedelic drugs like LSD and psilocybin that are being studied for treating depression and PTSD. While some research claims these drugs are beneficial, many studies have serious flaws including hiding negative side effects and being influenced by money from pharmaceutical companies. The author concludes that we need much better research before these drugs can be safely approved for medical use.

The safety and efficacy of Houtou Jianweiling tablet in patients with chronic non-atrophic gastritis: a double-blind, non-inferiority, randomized controlled trial

mycolabadmin

This study tested a traditional Chinese herbal medicine called Houtou Jianweiling Tablet against omeprazole, a common stomach medication, for treating chronic stomach inflammation. The herbal tablet worked just as well as the conventional drug at relieving stomach pain, bloating, and reducing harmful bacteria, while being very safe with almost no side effects. This suggests that people with mild to moderate stomach inflammation could use this natural herbal alternative instead of, or alongside, conventional medications.

Online Availability of Diamond Shruumz Before and After FDA Recall Initiation: Qualitative Assessment and Simulated Test Purchasing

mycolabadmin

Diamond Shruumz mushroom-based edible products caused severe illnesses in consumers and were recalled by the FDA in June 2024. Researchers discovered that despite the recall, many online sellers continued to advertise and sell these products across social media and websites. The study found that even two weeks after the recall, about one-third of the websites still successfully completed product sales, showing how difficult it is for regulators to enforce recalls on the internet.

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring

mycolabadmin

Researchers tested whether psilocybin could help postpartum depression in mice, but found it actually made things worse for both mothers and their babies. While psilocybin normally reduces depression and anxiety, it had the opposite effect during the postpartum period, making mothers more anxious and disrupting their care of pups. Babies exposed to psilocybin through breastfeeding or direct exposure developed anhedonia (inability to feel pleasure) as adults. These findings suggest that the postpartum period may be a particularly vulnerable time for psychedelic use, and more research is needed before considering these drugs for postpartum depression treatment.

Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish (Danio rerio)

mycolabadmin

Researchers tested 13 mind-altering drugs on developing zebrafish to see if they cause birth defects or behavioral problems. They found that psychedelics like psilocybin and ketamine were relatively safe for developing organisms, but traditional drugs of abuse like cocaine and methamphetamine caused significant behavioral changes without obvious physical defects. The study provides important safety information for these compounds, especially for pregnant or nursing individuals considering their use for therapeutic purposes.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

This study reviewed clinical trials comparing a newer antifungal drug called isavuconazole with other commonly used antifungal medications for treating serious fungal infections, particularly in patients with weakened immune systems. The research found that isavuconazole works just as well as other antifungal drugs but may have fewer side effects, especially liver problems. When compared directly with voriconazole, isavuconazole showed fewer drug-related side effects overall, making it a good alternative option for patients who cannot tolerate other antifungal treatments.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections in people with weakened immune systems. This study reviewed and analyzed three clinical trials to compare how well isavuconazole works compared to other antifungal drugs. The results showed that isavuconazole is just as effective as other antifungals but has fewer side effects, particularly fewer problems with liver health and drug-related adverse events. This makes isavuconazole a good alternative choice for patients who cannot use other antifungal medications or who are at risk of liver damage.

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Promoting rational herb-drug use through pharmacy-led advice and home visits in NCD patients

mycolabadmin

This study showed that when pharmacists visited NCD patients at home and provided education about the risks of combining herbal products with prescribed medications, patients significantly improved their knowledge and safe usage behaviors. The intervention successfully reduced the number of patients at risk of harmful herb-drug interactions from 37.5% to 25%. The findings suggest that simple home-based pharmacist counseling can be an effective way to help chronic disease patients safely use both herbs and medications together.

Research Topic: drug safety